|Awarded On||February 21, 2019|
|Title||Development of a Novel Oncolytic Vaccinia Virus Variant Suitable for Systemic Delivery|
|Program||Product Development Research|
|Award Mechanism||Seed Awards for Product Development Research|
|Institution/Organization||Icell Kealex Therapeutics LLC|
|Principal Investigator/Program Director||Shautong Song|
|Cancer Sites||All Sites|
*Pending contract negotiation
While cure rates for several cancers have significantly improved over the last decades, the outcome for patients with advanced solid tumors remains grimly unchanged, underscoring the need for new therapies. Oncolytic (cancer destroying) vaccinia virus (VV) is an appealing addition to the current cancer therapies due to its preference for infecting and killing tumor cells and a potential for activating the immune system component called T-cells that can travel to distant sites and kill any tumor cells they find, even those not infected by the virus.
At present, a desirable systemic intravenous administration of the virus is not feasible due to the strong immune response against it. In addition...